19Jul 2021
Secondary prevention of congenital CMV infection with valaciclovir following maternal primary infection in early pregnancy

Secondary prevention of congenital CMV infection with valaciclovir following maternal primary infection in early pregnancy

CMV maternal primary infection (MPI) in early pregnancy is the main risk factor of congenital infection with long‐term sequelae. To evaluate the ability of high dose maternal oral valaciclovir (VACV) to prevent fetal infection in the first trimester of pregnancy. Longitudinal cohort of CMV MPI prior to 14 weeks of gestation and diagnosed by serology screening in the first trimester based upon IgM, IgG and IgG avidity measurements between 2009 and 2020. This is a case‐control study using propensity score matching...

  • #gynaecology - ivf

Like

Save

Share